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 1 
Abstract 1 
Objectives: The exact aetiopathogenesis of microdamage induced long bone 2 
fractures remains unknown. These fractures are likely the result of inadequate 3 
bone remodeling in response to damage. This study  identifies an association 4 
of osteocyte apoptosis, the presence of osteocytic osteolysis and any 5 
alterations in sclerostin expression with fracture of the third metacarpal bone 6 
of (Mc-III) thoroughbred (TB) racehorses.  7 
Methods: 30 Mc-III bones were obtained; 10 from bones fractured during 8 
racing, 10 from the contralateral limb and 10 from control horses. Each Mc-III 9 
bone was divided into fracture site, condyle, condylar groove and sagittal 10 
ridge. Microcracks and diffuse microdamage were quantified. Apoptotic 11 
osteocytes were measured using TUNEL staining. Cathepsin K, matrix 12 
metalloproteinase -13 (MMP-13), HtrA1 and sclerostin expression was 13 
analysed.  14 
Results: In the fracture group microdamage was elevated 38.9±2.6% 15 
compared to controls.  There was no difference in osteocyte number and % 16 
of apoptotic cells between contralateral limb and unraced control, however, 17 
there were significantly less apoptotic cells in fractured samples (p<0.02). 18 
Immunohistochemistry showed that in the deep zones of the fractured 19 
samples sclerostin expression was significantly higher (p<0.03) of the total 20 
number of osteocytes. No increase in cathepsin K, MMP-13 or HtrA1 was 21 
present. 22 
 2 
Conclusions: There is increased microdamage in Mc-III bones that have 23 
fractured during racing. In this study this is not associated with osteocyte 24 
apoptosis or osteocytic osteolysis. The finding of increased sclerostin in the 25 
region of overt fracture suggests that this protein may be playing a key role in 26 
the regulation of bone microdamage during stress adaptation.  27 
 28 
 29 
Article summary  30 
 31 
Article focus 32 
 33 
This study identifies evidence for non-apoptotic bone remodelling 34 
mechanisms by osteocytes in microdamaged bone. 35 
 36 
Secondly this study investigate whether the wnt signaling protein sclerostin 37 
is altered in fractured bone. 38 
 39 
 40 
Key messages 41 
 42 
This study found that targeted remodelling in the bone is not dependent on 43 
osteocyte apoptosis. 44 
 45 
The key finding is a marked increase in the wnt signalling inhibitor 46 
sclerostin, suggesting that this protein may be produced at sites of high 47 
bone density to reduce further bone deposition playing a key role in the 48 
regulation of bone microdamage during stress adaptation. 49 
 50 
 51 
Strengths and limitations of this study 52 
 53 
This study has strong clinical sample size (n=30) of distal Mc-III bones both 54 
fractured and non-fractured Thoroughbred horses.  55 
 56 
This study indicate that microdamage in the racehorse has a fundamentally 57 
different pathological process to that modelled in small rodent animals and 58 
these results should be further validated in human fracture model.  59 
 60 
 61 
 3 
Introduction 62 
Long bone fractures in horses have significant welfare and economic 63 
implications to the horseracing industry. Key to the prevention of fractures is 64 
a clear understanding of their aetiopathogenesis. In horses, long bone 65 
fractures occur either due to a one off overload incident or due to repetitive 66 
microdamage and subsequent weakening usually associated with high 67 
intensity exercise.  Fractures resulting from microdamage are commonly 68 
termed ‘stress fractures’ and often present as catastrophic fractures at 69 
exercise (1). In the UK the most recent study of days lost from training by two 70 
or three year old Thoroughbred (TB) horses showed that lameness was the 71 
most important cause of lost training days. Stress fractures were the most 72 
important cause of lameness, with an incidence of 1.48 and 1.43/100 per 73 
horse months in 2 and 3 year old horses respectively (2, 3). A number of 74 
bones are affected by stress fracture, including the carpal bones, proximal 75 
sesamoid bones, tibia and humerus with the distal condyle of the third 76 
metacarpal bone (MCIII) being one of the most common sites affected (4, 5). 77 
 78 
The TB racehorse runs at speeds exceeding 15 m/s, applying highly repetitive 79 
surface strains of >5000 to MCIII (6) which leads to microdamage 80 
accumulating in the joint surface and adjacent subchondral bone plate (7, 8). 81 
This damage is observed to have distinct two histological forms, linear 82 
microcracks or diffuse microdamage (9-11). During these high intensity 83 
exercise regimes, a process of ‘targeted bone remodelling’ is used to repair 84 
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the microdamage (12).  Bone remodelling in the body requires the coupling of 85 
bone resorption and formation and occurs to maintain mineral homeostasis, 86 
to adapt to mechanical change and to repair damage – the latter two 87 
scenarios are site-specific and are termed ‘targeted remodelling’ (12).   88 
 89 
Stress fracture is likely a result of inadequate targeted remodelling in 90 
response to microdamage, when bone resorption exceeds bone formation, 91 
leading to weakened bone and overt fracture lines are propagated. Targeted 92 
remodelling is controlled by osteocytes (13) that have a number of key roles 93 
in bone homeostasis, including the regulation of bone formation, the control 94 
of bone resorption via both apoptotic and non-apoptotic pathways, RANKL 95 
mediated signals and the transduction of mechanical signals to induce an 96 
appropriate biological response (13, 14). The regulation of bone formation by 97 
osteocytes is predominately via sclerostin production, a wnt signalling 98 
inhibitor that inhibits bone formation (15) and is modulated by local load (16)). 99 
Inhibition of sclerostin with neutralizing antibodies has also been shown to 100 
speed up fracture healing (17) and sclerostin knockout mice have been shown 101 
to have faster fracture healing (18), providing evidence that sclerostin may 102 
inhibit bone healing in vivo. Non-apoptotic mechanisms of bone remodelling 103 
include direct remodelling of the perilucunar bone (‘osteocytic osteolysis’) (13). 104 
Osteocytic osteolysis takes place via the production by osteocytes of 105 
degradative enzymes, such as Cathepsin K (19), MMP 13 (20)  and the serine 106 
protease HtrA1 (21) as well as the classic osteoclast enzyme, TRAP, and 107 
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these enzymes can be used as surrogate markers for this process. However, 108 
whilst some studies in the TB have investigated the role of osteocytic 109 
apoptosis in stress fractures, no studies have been performed in horses to 110 
investigate wnt signalling pathways or direct remodelling in microdamaged 111 
bone. 112 
 113 
This study  identifies evidence for non-apoptotic bone remodelling 114 
mechanisms by osteocytes in microdamaged bone and to investigate whether 115 
the wnt signaling protein sclerostin is altered in microdamaged bone.  116 
 117 
 118 
Methods 119 
Animals Third metacarpal (Mc-III) bones were obtained from Thoroughbred 120 
racehorses that were euthanased as a result of catastrophic fracture on the 121 
racetrack in California, U.S.A. and collected as part of the California Horse 122 
Racing Board post-mortem programme (Figure 1). The study groups were as 123 
follows: Group F distal Mc-III lateral condylar fractures that occurred on the 124 
racetrack immediately prior to euthanasia (n=10), Group CL (n=10) distal MC-125 
III contralateral (uninjured) leg from horses in Group F (n=10). Horses with 126 
bilateral fractures were excluded as where those with concurrent fracture 127 
pathology. Group C distal Mc-III obtained from Thoroughbred horses that had 128 
sustained fatal non-orthopaedic injuries on the racetrack (n = 10). For Groups 129 
F and CL the horse mean age was 4.1 +/- 1.2 years, for Group C the horse 130 
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mean age was 3.9 +/- 1.5 years. For all samples, distal thoracic limbs were 131 
transected at the level of the carpal bone and stored at -20 ⁰C after humane 132 
euthanasia. 133 
 134 
Specimen preparationA dorso-proximal palmaro-distal frontal plane bone 135 
block of the distal Mc-III (22, 23) approximately 1 cm thick was prepared using 136 
a band saw. The bone block of the joint surface was then divided into four 137 
pieces using sagittal plane cuts to create separate blocks of each of the 138 
regions-of-interest: lateral condyle fracture site, medial condyle, medial 139 
condylar groove and sagittal ridge (23) (Figure 2). 140 
 141 
Preparation of tissue sections For each site both frozen and 142 
polymethylmethacrylate (PMMA) sections were obtained.  Frozen samples 143 
were subsequently used for immunohistochemistry, PMMA samples for 144 
histological staining. Frozen sections were produced by embedding with OCT 145 
Cryoembedding Compound (SDLAMB/OCT, Fisher) and snap-freezing in 146 
liquid nitrogen. Sections of 10 μm thickness were made through the central 147 
portion of the bone block using a crysotat. The unfixed and non-demineralized 148 
tissue cryosections were tape transferred and glued to slides with UV 149 
sensitive glass adhesive. PMMA sections were obtained as follows. Bone 150 
blocks were fixed in 70% ethanol and bulk-stained in 1% basic fuchsin (JT 151 
Baker® Basic Fuchsin, JTB-B660-03, SureChem Products Ltd) in a graded 152 
series of ethanols (80%, 90%, 100%) for a total staining time of 18 days 153 
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allowing thorough penetration of stain and dehydration of the bones. After 154 
embedding in PMMA, 20 m calcified oblique frontal plane sections were 155 
prepared from the centre of each block. This basic acid Fuchsin technique 156 
stains  microcracks and diffuse matrix damage that existed before histologic 157 
sectioning (24).  158 
 159 
Visualisation of microdamage PMMA sections were dehydrated, mounted 160 
in DPX mounting medium (44581, Sigma) and dried. Sections were imaged 161 
using a Fluorescence Microscope (Leica, DMRB) and over 200 microscope 162 
images per section were stitched together using Surveyor image analysis 163 
software and subsequently analysed with ImageJ software.  The number of 164 
microcracks were quantified by expressing the number of cracks per section 165 
normalized to the total length of the cartilage/subchondral bone interface for 166 
each section. Branched cracks were counted as one crack and each section 167 
was scored blind by the same observer to ensure consistency between data 168 
collection. Diffuse damage was quantified by expressing the number of 169 
discrete areas of diffuse damage section normalized to the total length of the 170 
cartilage/subchondral bone interface for each section. 171 
 172 
Quantification of osteocyte apoptosis The prevalence and location of 173 
apoptotic osteocytes/osteoblasts was detected using The DeadEnd™ 174 
Fluorometric TUNEL System (G3250, Promega).  175 
 176 
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Briefly, the cryosections were fixed by immersing slides in freshly prepared 177 
4% methanol-free formaldehyde solution in PBS (pH 7.4) for 5 minutes at 178 
room temperature. The slides were washed by immersing in PBS for 5 179 
minutes.  Incubation in Proteinase K solution (20μg/ml) was used to 180 
permeabilize tissue sections. Sections were then incubated with nucleotide 181 
mix and rTdT enzyme at 37°C for 60 minutes. As a negative control sections 182 
without the rTdT enzyme were used. The sections were mounted in 183 
VECTASHIELD® + DAPI (Vector Lab Cat. H-1200) to stain nuclei and 184 
immediately analyzed under a fluorescence microscope Nikon Ti-E Perfect 185 
Focus System using a standard fluorescein filter set to view the green 186 
fluorescence of fluorescein at 520 ± 20 nm and blue DAPI at 460 nm under a   187 
10x objective. All the nuclei of osteocytes (both live DAPI at 460 nm and dead 188 
green fluorescein at 520 nm) were counted with ImageJ software using 189 
particle analysis in the Nucleus counter plugin. All the dead cells were 190 
quantified counting only green fluorescein nuclei with ImageJ software using 191 
particle analysis in the Nucleus counter plugin. From each site a 192 
representative area of 0.1 mm² (about 380x280  μm) was analysed from the 193 
surface of four different anatomical regions (condyle, condylar groove, sagittal 194 
ridge and fracture site).  195 
 196 
Immunohistochemistry Frozen sections were labelled with Rb pAb 197 
Sclerostin (Ab63097, Abcam), Rb pAb HtrA1 (Ab38611, Abcam), Ms mAB 198 
Cathepsin K (Ab66267, Abcam) and Ms mAb MMP13 (Ab3208, Abcam) using 199 
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anti-Mouse IgG (071M6210, Sigma) and anti-Rabbit IgG (B8895, Sigma) 200 
secondary antibodies.  A horse-radish peroxidase detection (HRP) method 201 
was used to detect staining and sections were then counter stained with 202 
Toludine Blue or Methyl Green to allow visual identification of the cells. 203 
Sections were examined using bright field optics on a Leica DMRXA2 with a 204 
QImaging Retiga EX fast 1394 camera system under a x60 and x100 205 
objective. At each of the anatomical sites, the total number of osteocytes and 206 
the positively labelled osteocytes were quantified in an area of 1 mm² in the 207 
subchondral bone (immediately beneath the cartilage/bone interface, 208 
(‘surface zone’) and in an area of 1 mm² immediately below this (‘deep zone’) 209 
5 to 10 mm below surface zone. 210 
 211 
Statistics All samples were processed in order to collect four technical 212 
replicates for each experiment and the data are presented as the mean ± 213 
standard deviation (SD) with the significance level set at 0.05. The data were 214 
evaluated using Student’s t test, ANOVA and non-parametric Mann-Whitney 215 
to determine statistically significant differences with GraphPad Prism 5 216 
software. 217 
 218 
 219 
Results 220 
Microdamage quantification  221 
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In order to visualize the microdamage within the bones, the whole bone was 222 
stained prior to sectioning.  This was done to ensure that damage produced 223 
during the processing would not be stained and would therefore be excluded 224 
from damage quantification (23, 25).  225 
 226 
This study identified both microcracks and diffuse damage in the samples 227 
studied (Figure 3). There was significantly increased microcrack damage/area 228 
in the lateral condyle fracture site of Group F (7.04 +\- 2.91 cracks/mm2) 229 
compared to the contralateral limb (Group CL) (3.18 +\- 4.26 cracks/mm2) and 230 
the control horses (Group C) (2.93 +\- 3.85 cracks/mm2), p=0.002 and 231 
p=0.005, respectively.  When the total microcrack damage was compared for 232 
the other 3 sites there was no significant difference between sites.  There was 233 
no significant difference between experimental groups at any site in the 234 
amount of diffuse damage/area with Group F having 3.43 +\- 1.5 discrete 235 
areas of staining compared to 2.92 +\- 1.45 in Group CL and 2.55 +\- 1.67 in 236 
Group C. 237 
 238 
 239 
Quantification of apoptosis  240 
The DeadEnd fluorometric apoptosis analysis detected apoptotic cells in all 241 
samples studied (Figure 4). When data from all 4 sites was pooled, there were 242 
significantly fewer apoptotic osteocytes in Group F compared to Group CL 243 
(p=0.002) but no difference in the percentage apoptotic osteocytes recorded 244 
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when comparing with raced horses (Group F + CL) and Group C. The 245 
difference was greatest on the sagittal ridge where the rate of apoptotic cells 246 
was 22.2±11.0% in Group F compared to 47.0±19.6% in Group CL (p=0.007). 247 
 248 
Enzyme Immunohistochemistry 249 
MMP-13, HtrA1 and Cathepsin K immunoreactivity was detected in all 250 
samples studied.  Positive staining was detected in the cytoplasm of the 251 
osteocytes in the bone.  MMP-13, HtrA1 and Cathepsin K immunoreactivity 252 
was not different among groups or anatomical sites (Figure 5).  253 
 254 
Sclerostin immunolocalisation 255 
Sclerostin immunoreactivity was detected in all samples studied (Figure 6). 256 
Positive staining was detected in the cytoplasm of the osteocytes in the bone.  257 
No staining was detected in the cartilage or within the blood vessels. No 258 
differences between sites was detected except in the lateral condylar fracture 259 
site groove.  At this site sclerostin immunohistochemistry showed that, in the 260 
subchondral bone under the articular surface (‘surface zone’) staining was in 261 
the range of 3.9+/- 2.9% of osteocytes staining positive for sclerostin in all 262 
samples studied.  In the deep zone however, sclerostin 263 
immunohistochemistry showed that there was a significant increase in 264 
positive staining in Group F compared to Group CL, with a mean of 24.4 +/- 265 
19.4% of osteocytes staining positive for sclerostin (p=0.03) (Figure 7). 266 
 267 
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 268 
Discussion 269 
In this study we have shown that osteocyte apoptosis is not increased in 270 
regions of microdamage in the MCIII of TB racehorses in California that 271 
sustain fatal lateral condylar fractures. We have demonstrated increased 272 
levels of a wnt signalling inhibitor protein, sclerostin, associated with the 273 
fracture line in the fractured bones, but no evidence of osteocytic osteolysis 274 
in these samples. Our results suggest that wnt signalling pathways may be 275 
important in the aetiopathogenesis of microdamage induced stress fracture in 276 
the TB racehorse. 277 
 278 
Microdamage has been documented in numerous TB racehorse fractures as 279 
evidence of pre-fracture pathology (26, 27). In this study we confirmed that 280 
our samples had microdamage similar to that reported in previous studies by 281 
pre-sectioning staining of the samples with acid Fuchsin, ensuring that the 282 
microdamage identified was not caused by sample preparation (24).  We 283 
identified a mean of 7.04 +/- 2.91 microcracks/mm2 joint surface in fractured 284 
bones, which is consistent with a previous report (22), and indicated that the 285 
samples included in the study were representative of stress induced 286 
microdamage as reported previously in the literature.   287 
 288 
It has long been proposed that the development of linear fracture microcracks 289 
through repetitive experimental loading is associated with a loss of osteocyte 290 
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viability in the region of the microcrack and the areas that subsequently 291 
formed resorption spaces (28, 29). These, and other, observations led to the 292 
concept that the osteocyte has a role as a mechanoreceptor in bone, sensing 293 
load and regulating bone adaptation (16). A number of small animal in vivo 294 
studies have demonstrated that, in these acute models (7-10d experiments), 295 
osteocytes regulate bone formation through an apoptosis-mediated 296 
mechanism (30-32). This mechanism is currently considered to underlie the 297 
control targeted remodelling of microdamage. However, these acute small 298 
animal experiments, primarily conducted in the rat ulnar fatigue damage 299 
model, evaluate very different events compared to the chronic, high velocity 300 
overloading of the McIII experienced by the TB racehorse and may underlie 301 
why, in this study, the naturally occurring microdamage is not associated with 302 
osteocyte apoptosis. Our observations agree with previous studies in the 303 
equine distal MCIII.  In other studies, no association between targeted 304 
remodelling and osteocytes apoptosis has been demonstrated (8, 33). Taken 305 
together these studies suggest that targeted remodelling in the racehorse is 306 
not dependent on osteocyte apoptosis, but that an alternative mechanism of 307 
regulation may be involved. 308 
 309 
In the rat ulnar model of microdamage, it has been hypothesised that 310 
osteocyte apoptosis stimulates bone remodelling initially via osteoclastic 311 
resorption (34). However, osteocytes can regulate bone remodelling via other 312 
mechanisms, for example by osteocytic osteolysis and wnt-signalling 313 
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pathways (35). In osteocytic osteolysis osteocytes directly resorb their 314 
surrounding environment via a cathepsin K and/or MMP13 associated 315 
mechanism (36, 37). In this study we did not find an association between 316 
Cathepsin K, MMP13 or HtrA1 immunoreactivity and bone damage, 317 
suggesting that osteocytic osteolysis through Cathepsin K, MMP13 or HtrA1 318 
pathways is not linked to microdamage in the racehorse. 319 
 320 
In contrast, however, there was evidence for an association between the wnt 321 
signalling pathway and microdamage. Osteocytes regulate bone formation 322 
primarily via their production of the wnt signalling protein sclerostin, that 323 
inhibits bone formation (15) and responds to local load (16).  In this study we 324 
identified sclerostin protein in osteocytes in all samples studied, however, we 325 
detected a marked and significant increase in sclerostin positive osteocytes 326 
along the fractured line. This finding of increased sclerostin in the region of 327 
the fracture was unexpected; in rat ulnar models of stress fracture sclerostin 328 
has been reported as reduced adjacent to the fracture line (38), albeit over 329 
the short time courses of the experiment.  However, in association with the 330 
finding that osteocyte apoptosis is not associated with equine microdamage 331 
but is with rat ulnar microdamage, these results indicate that microdamage in 332 
the racehorse may have a fundamentally different pathological process to that 333 
modelled in small animals.  334 
 335 
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The presence of increased sclerostin associated with an overt fracture line in 336 
these cases of equine stress fracture is intriguing.  One explanation is that the 337 
increase in sclerostin is a direct result of increased bone density at the site of 338 
the microdamage and that sclerostin – an inhibitor of bone formation - is being 339 
produced locally to prevent further, supra-physiological bone mass increases 340 
which causes increased stiffness and likelihood of fracture.  Racehorse 341 
training does cause increased bone density in the distal Mc-III (39, 40) and 342 
this bone density has been shown to be heterogenous across the distal Mc-343 
III (40-42). It has been suggested that these bone density gradients within the 344 
bone further drive the formation of microdamage. The observation that 345 
sclerostin is increased at the site of fracture might suggest that sclerostin is 346 
being upregulated here to inhibit ‘excessive’ bone formation prevent 347 
worsening bone density gradients that may ultimately lead to overt fracture. 348 
However, the fact that the increased sclerostin was only seen in the overtly 349 
fractured bones, rather than in the contralateral limb which has experienced 350 
similar racing and training, indicates that the increased sclerostin could be an 351 
end stage event associated with high probability of fracture.  Sclerostin is 352 
upregulated by unloading of bone (‘stress shielding’) (43, 44), it may be that 353 
local unloading caused by heterogenous bone density changes is acting as 354 
the mechanism to drive this increased sclerostin expression. The possibility 355 
that sclerostin might play a role in reducing the physiological consequences 356 
of ‘excessive bone’ mass has also been suggested by the finding that 357 
constitutive activation of osteocyte -catenin in mice increased bone mass 358 
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(38), but led to significantly increased serum sclerostin levels, suggested by 359 
these authors to be a protective mechanism.   360 
 361 
There are a number of limitations with this study.  One limitation is that the 362 
samples studied do not allow an accurate determination of when the observed 363 
increase in sclerostin occurred relative to the fracture.  The observed increase 364 
in sclerostin could have been produced prior to fracture, between fracture and 365 
death or, less likely, post mortem. The horses included in this study were 366 
euthanased within 10 minutes of fracture occurring, which compares 367 
favourably with the longer time between naturally occurring fracture and bone 368 
sample acquisition in similar studies in man (fractured neck of femur). 369 
However, it has been shown that sclerostin levels in fracture haematoma are 370 
significantly increased compared to serum levels, indicating that sclerostin is 371 
indeed induced by fracture (45) and future studies should ensure extremely 372 
rapid collection and fixation of samples prior to processing. 373 
Another limitation of this study is that sclerostin was only investigated in the 374 
distal metacarpus.  Further work is required to investigate fractures at other 375 
anatomical sites and also to investigate any relationship between the levels 376 
of training/racing undergone by the horse and sclerostin levels. 377 
 378 
In conclusion, this study finds no evidence for a role of osteocyte apoptosis 379 
or osteocytic osteolysis in the stress fractures of Mc-III of the TB racehorse.  380 
However, a marked increase in the wnt signalling inhibitor sclerostin was 381 
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detected, suggesting that this protein may be produced to reduce further bone 382 
deposition as an end stage event in a bone that has remodelled too far to 383 
sustain its integrity. 384 
 385 
 386 
References 387 
1. Parkin TD, Clegg PD, French NP, Proudman CJ, Riggs CM, Singer ER, et al. 388 
Risk of fatal distal limb fractures among Thoroughbreds involved in the five 389 
types of racing in the United Kingdom. The Veterinary record. 390 
2004;154(16):493-7. 391 
2. Dyson PK, Jackson BF, Pfeiffer DU, Price JS. Days lost from training by 392 
two- and three-year-old Thoroughbred horses: a survey of seven UK training 393 
yards. Equine veterinary journal. 2008;40(7):650-7. 394 
3. Owen KR, Dyson SJ, Parkin TD, Singer ER, Kristoffersen M, Mair TS. 395 
Retrospective study of palmar/plantar annular ligament injury in 71 horses: 396 
2001-2006. Equine veterinary journal. 2008;40(3):237-44. 397 
4. Radtke CL, Danova NA, Scollay MC, Santschi EM, Markel MD, Da Costa 398 
Gomez T, et al. Fatigue fracture of the condyles of the third metacarpal/third 399 
metatarsal bone in Thoroughbred racehorses. Am J Vet Res. 2003;64:1110-6. 400 
5. Boyde A, Haroon Y, Jones SJ, Riggs CM. Three dimensional structure of the 401 
distal condyles of the third metacarpal bone of the horse. Equine veterinary 402 
journal. 1999;31(2):122-9. 403 
6. Nunamaker DM, Butterweck DM, Provost MT. Fatigue fracrture in 404 
thoroughbred racehorses: relationships with age, peak bone strain and training. 405 
J Orthop Res. 1990;8:604-11. 406 
7. Muir P, McCarthy J, Radtke CL, Markel MD, Santschi EM, Scollay MC, et al. 407 
Role of endochondral ossification of articular cartilage and functional adaptation 408 
of the subchondral plate in the development of fatigue microcracking of joints. 409 
Bone. 2006;38:342-9. 410 
8. Muir P, Peterson AL, Sample SJ, Scollay MC, Markel MD, Kalscheur VL. 411 
Exercise-induced metacarpophalangeal joint adaptation in the Thoroughbred 412 
racehorse. J Anat. 2008;213:706-17. 413 
9. Vakil JJ, O'Reilly MP, Sutter EG, Mears SC, Belkoff SM, Khanuja HS. Knee 414 
arthrotomy repair with a continuous barbed suture: a biomechanical study. The 415 
Journal of arthroplasty. 2011;26(5):710-3. 416 
10. Kawcak CE NR, McIlwraith CW, Trotter GW. Sucbchondral bone reaction 417 
to exercise. AAEP Proceedings 1999(45):2. 418 
11. Bentley VA, Sample SJ, Livesey MA, Scollay MC, Radtke CL, Frank JD, et al. 419 
Morphologic changes associated with functional adaptation of the navicular 420 
bone of horses. Journal of anatomy. 2007;211(5):662-72. 421 
 18 
12. Burr DB. Targeted and nontargeted remodeling. Bone. 2002;30:2-4. 422 
13. Bonewald LF. The amazing osteocyte. J Bone Min Res. 2011;26:229-38. 423 
14. Schaffler MB, Kennedy OD. Osteocyte signalling in bone. Curr Osteoporos 424 
Res. 2012;10:116-25. 425 
15. Larsson S. Anti-sclerostin - is there an indication? Injury. 2016;47 Suppl 426 
1:S31-5. 427 
16. Nguyen J, Tang SY, Nguyen D, Alliston T. Load regulates bone formation 428 
and Sclerostin expression through a TGFβ-dependent me. PLoS One. 429 
2013;8:e53813. 430 
17. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, et al. Inhibition of 431 
sclerostin by monoclonal antibody enhances bone healing and improves bone 432 
density and strength of nonfractured bones. Journal of bone and mineral 433 
research : the official journal of the American Society for Bone and Mineral 434 
Research. 2011;26(5):1012-21. 435 
18. Li C, Ominsky MS, Tan HL, Barrero M, Niu QT, Asuncion FJ, et al. Increased 436 
callus mass and enhanced strength during fracture healing in mice lacking the 437 
sclerostin gene. Bone. 2011;49(6):1178-85. 438 
19. Wysolmerski JJ. Osteocytes remove and replace perilacunar mineral 439 
during reproductive cycles. Bone. 2013;54:230-6. 440 
20. Tang SY, Herber RP, Ho SP, Alliston T. Matrix metalloproteinase-13 is 441 
required for osteocytic perilacunar remodelling and maintains bone fracture 442 
resistance. J Bone Min Res. 2012;27:1936-50. 443 
21. Tsuchiya A, Yano M, Tocharus J, Kojima H, Fukomoto M, Kawaichi M, et al. 444 
Expression of mouse HtrA1 serine protease in normal bone and cartilage and its 445 
upregulation in joint cartilage damaged by experimental arthritis. Bone. 446 
2005;37:323-36. 447 
22. Riggs CM, Whitehouse GH, Boyde A. Structural variation of the distal 448 
condyles of the third metacarpal and third metatarsal bones in the horse. Equine 449 
veterinary journal. 1999;31(2):130-9. 450 
23. Muir P, Peterson AL, Sample SJ, Scollay MC, Markel MD, Kalscheur VL. 451 
Exercise-induced metacarpophalangeal joint adaptation in the Thoroughbred 452 
racehorse. Journal of anatomy. 2008;213(6):706-17. 453 
24. Bentolila V, Boyce TM, Fyhrie DP, Drumb R, Skerry TM, Schaffler MB. 454 
Intracortical remodeling in adult rat long bones after fatigue loading. Bone. 455 
1998;23(3):275-81. 456 
25. Burr DB, Hooser M. Alterations to the en bloc basic fuchsin staining 457 
protocol for the demonstration of microdamage produced in vivo. Bone. 458 
1995;17(4):431-3. 459 
26. van Oers RF, van Rietbergen B, Ito K, Huiskes R, Hilbers PA. Simulations 460 
of trabecular remodeling and fatigue: is remodeling helpful or harmful? Bone. 461 
2011;48(5):1210-5. 462 
27. Vallance SA, Spriet M, Stover SM. Catastrophic scapular fractures in 463 
Californian racehorses: pathology, morphometry and bone density. Equine 464 
veterinary journal. 2011;43(6):676-85. 465 
 19 
28. Bentolila V, Boyce TM, Fyhrie DP, Drumb R, Skerry TM, Schaffler MB. 466 
Intracortical remodeling in adult rat long bones after fatigue loading. Bone. 467 
1998;23:275-9. 468 
29. Verborgt O, Gibson GJ, Schaffler MB. Loss of osteocyte integrity in 469 
association with microdamage and bone remodelling after fatigue in vivo. J Bone 470 
Min Res. 2000;15:60-70. 471 
30. Cardoso L, Herman BC, Verborgt O, Laudier DM, Majeska RJ, Schaffler MB. 472 
Osteocyte apoptosis controls activation of intracortical resorption in response 473 
to bone fatigue. J Bone Miner Res. 2009;24:597-605. 474 
31. Noble BS, Peet N, Stevens HY, Brabbs A, Mosley JR, Reilly GC, et al. 475 
Mechanical loading:biphasic osteocyte survival and targetting of osteoclasts for 476 
bone destruction in rat cortical bone. Am J Physiol Cell Physiol. 2003;284:C934-477 
43. 478 
32. Vashishth D, Verborgt D, Divine G, Schaffler MB, Fyhrie DP. Decline in 479 
osteocyte lacunar density in human cortical bone is associated with 480 
accumulation of microcracks with age. Bone. 2000;26:375-80. 481 
33. Da Costa Gómez TM, Barrett JG, Sample SJ, Radtke CL, Kalscheur VL, Lu Y, 482 
et al. Up-regulation of site-specific remodeling without accumulation of 483 
microcracking and loss of osteocytes. Bone. 2005;37:16-24. 484 
34. Kennedy OD, Herman BC, Laudier DM, Majeska RJ, Sun HB, Schaffler MB. 485 
Activation of resorption in fatigue-loaded bone involves both apoptosis and 486 
active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone. 487 
2012;50(5):1115-22. 488 
35. Prideaux M, Findlay DM, Atkins GJ. Osteocytes: The master cells in bone 489 
remodelling. Current opinion in pharmacology. 2016;28:24-30. 490 
36. Tang SY, Herber RP, Ho SP, Alliston T. Matrix metalloproteinase-13 is 491 
required for osteocytic perilacunar remodeling and maintains bone fracture 492 
resistance. Journal of bone and mineral research : the official journal of the 493 
American Society for Bone and Mineral Research. 2012;27(9):1936-50. 494 
37. Qing H, Ardeshirpour L, Pajevic PD, Dusevich V, Jahn K, Kato S, et al. 495 
Demonstration of osteocytic perilacunar/canalicular remodeling in mice during 496 
lactation. Journal of bone and mineral research : the official journal of the 497 
American Society for Bone and Mineral Research. 2012;27(5):1018-29. 498 
38. Tu X, Delgado-Calle J, Condon KW, Maycas M, Zhang H, Carlesso N, et al. 499 
Osteocytes mediate the anabolic actions of canonical Wnt/beta-catenin 500 
signaling in bone. Proceedings of the National Academy of Sciences of the United 501 
States of America. 2015;112(5):E478-86. 502 
39. Riggs CM, Boyde A. Effect of exercise on bone density in distal regions of 503 
the equine third metacarpal bone in 2-year-old thoroughbreds. Equine 504 
veterinary journal Supplement. 1999(30):555-60. 505 
40. Loughridge AB, Hess AM, Parkin TD, Kawcak CE. Qualitative assessment 506 
of bone density at the distal articulating surface of the third metacarpal in 507 
Thoroughbred racehorses with and without condylar fracture. Equine 508 
veterinary journal. 2015. 509 
41. Stover SM, Murray A. The California Postmortem Program: leading the 510 
way. Vet Clin North Am Equine Pract. 2008;24(1):21-36. 511 
 20 
42. Ramzan PH, Powell SE. Clinical and imaging features of suspected 512 
prodromal fracture of the proximal phalanx in three Thoroughbred racehorses. 513 
Equine veterinary journal. 2010;42(2):164-9. 514 
43. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, et al. Sclerostin mediates bone 515 
response to mechanical unloading through antagonizing Wnt/beta-catenin 516 
signaling. Journal of bone and mineral research : the official journal of the 517 
American Society for Bone and Mineral Research. 2009;24(10):1651-61. 518 
44. Spatz JM, Wein MN, Gooi JH, Qu Y, Garr JL, Liu S, et al. The Wnt Inhibitor 519 
Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro. The 520 
Journal of biological chemistry. 2015;290(27):16744-58. 521 
45. Sarahrudi K, Thomas A, Albrecht C, Aharinejad S. Strongly enhanced 522 
levels of sclerostin during human fracture healing. Journal of orthopaedic 523 
research : official publication of the Orthopaedic Research Society. 524 
2012;30(10):1549-55. 525 
 526 
 527 
 528 
Figure legends 529 
 530 
Figure 1. Dorso-palmar radiographs of intact third metacarpal bone (A) and 531 
contralateral, fractured bone of same horse (B). Photograph of articular surfaces of 532 
intact bone (C) and contralateral fractured third metacarpal bone (D). 533 
 534 
Figure 2. Dorso-palmar radiographs of fractured third metacarpal bone (A) and 535 
contralateral bone (B).  The different regions used in the analysis of staining are 536 
shown. A = medial condyle, B = medial condylar groove, C = sagittal ridge and D = 537 
lateral condylar fracture site. In C the sampling site regions are shown, corresponding 538 
to A-D in B. 539 
 540 
Figure 3. A to C representative micrographs of acid Fuchsin labelled structures in 541 
metacarpal bones. A) Linear microcrack extending from articular surface, B) staining 542 
around blood vessels, C) diffuse microdamage extending from articular surface. D) 543 
Amount of damage per surface area of section shown for microcracks and diffuse 544 
damage. There is no difference in the amount of diffuse damage quantified in the 545 
three groups, however there is a statistically significant difference between the 546 
amount of microcrack damage/surface area in the lateral condyle (site D) compared 547 
to both contralateral and control bones. Scale bar 100 μm. F = fractured bones, Cl = 548 
contralateral bones and C = control bones. P<0.05 and indicated by ***. 549 
 550 
Figure 4. A) Quantification of apoptosis within osteocytes in non-fractured and 551 
fractured samples, B) Raced and non-raced samples and C) samples from the sagittal 552 
ridge. There is a statistically significant difference in the numbers of apoptotic cells 553 
(p<0.05) between non-fractured and fractured samples (A) and in the numbers of 554 
apoptotic cells on the sagittal ridge, with a significant increase in apoptotic cells in 555 
 21 
the contralateral limb samples (C). No difference was recorded in the numbers of 556 
osteocytes in the samples (D and E). F) Representative microscope image of a 557 
fluorometric TUNEL apoptosis analysis. Blue stain shows live cell nuclei, green stain 558 
shows apoptotic cells. Scale bar 100 μm. F = fractured bones, CL = contralateral 559 
bones and C = control bones. 560 
 561 
Figure 5. Representative photomicrographs of immunohistochemistry in osteocytes 562 
in the subchondral bone. A) MMP-13, B) Cathepsin K, C) HTrA1. Osteocytes stained 563 
positively are seen as black cells in the fractured samples. In A) the cartilage is stained 564 
with Toluidine Blue, in B) the cartilage is stained with methyl green. Scale bar 100 565 
μm. 566 
 567 
Figure 6. Representative photomicrographs of sclerostin immunohistochemistry. A) 568 
Subchondral bone area control sample, B) subchondral area fracture sample, C) deep 569 
zone control sample, D) deep zone fracture sample. Osteocytes (Arrowheads in A and 570 
C) stained positively for sclerostin are seen as black cells in B and D (Group F) and 571 
shown by black arrows. In A the cartilage is stained with Toluidine Blue. Scale bar 572 
100 μm. c= cartilage, scb = subchondral bone.  The cartilage is stained with Toluidine 573 
Blue and is visible in A and B.  The fracture site is to the bottom of the figures in C 574 
and D (black arrowhead). 575 
 576 
Figure 7. Quantification of sclerostin immunohistochemistry within osteocytes in 577 
fractured (F) and contralateral (CL) limbs.  There is a significant increase (* p<0.05) 578 
in sclerostin immunoreactivity in the deep zone of the fractured bone. In the 579 
photograph the approximate site of the cartilage/bone interface region (white arrow) 580 
and the deeper region is indicated (black arrow). 581 
 582 
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